Biomarkers /
ERCC3
Overview
Excision repair cross-complementation group 3 (ERCC3) is a gene that encodes a protein that is involved in nucleotide excision repair. Missense mutations, silent mutations, nonsense mutations, and in-frame deletions are observed in cancers such as colon cancer, skin cancer, and stomach cancer.
ERCC3 is altered in 1.19% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma, and squamous cell lung carcinoma having the greatest prevalence of alterations [3].
The most common alterations in ERCC3 are ERCC3 Mutation (1.03%), ERCC3 Nonsense (0.07%), ERCC3 Loss (0.05%), ERCC3 Amplification (0.04%), and ERCC3 V129I (0.02%) [3].
Clinical Trials
Significance of ERCC3 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.